Symptoms experienced after transcatheter arterial chemoembolization in patients with primary liver cancer: A network
Wei Xu1, Zheng Zhu1,2,3, Jingxian Yu4
1School of Nursing, Fudan University, Shanghai, China.
Objective:
This study aimed to establish a symptom network for patients with primary liver cancer posttranscatheter arterial chemoembolization (TACE), identifying core and bridge symptoms. The goal is to provide a foundation for precise and comprehensive nursing interventions.
Methods:
A total of 1207 post-TACE patients were included using a consecutive sampling method. Data collection involved a general information questionnaire, the Anderson Symptom Assessment Scale, and a primary liver cancer-specific symptom module. The symptom network was constructed using the R language.
Results:
In the overall network, distress exhibited the highest strength (r = 1.31) and betweenness (r = 62). Fatigue had the greatest closeness (r = 0.0043), while nausea and vomiting (r = 0.76 ± 0.02) had the highest marginal weights. Nausea had the highest bridge strength (r = 5.263). In the first-time TACE-treated symptom network, sadness (r = 5.673) showed the highest bridge strength, whereas in the non-first-time symptom network, fever (r = 3.061) had the highest bridge strength.
Conclusions:
Distress serves as a core symptom, and nausea acts as a bridge symptom after TACE treatment in liver cancer patients. Interventions targeting bridge symptoms should be tailored based on the number of treatments, enhancing the quality of symptom management.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
05:31Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology
Portal Hypertension
